Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 6653 results found since Jan 2013.
Increasing Influenza vaccination uptake rates in the 65-year-old population
Ir Med J. 2023 Aug 17;116(7):805.NO ABSTRACTPMID:37606210
Source: Ir Med J - August 22, 2023 Category: General Medicine Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality
CONCLUSIONS: Since 2021, changes in the dominant SARS-CoV-2 variant, vaccination rollout, and the shift of infection to younger ages have reduced SARS-CoV-2 infection ascertainment. The same factors, combined with the improvement of patient management and care, contributed to a massive reduction in the severity and fatality of COVID-19.PMID:37599801 | PMC:PMC10432583 | DOI:10.1111/irv.13181
Source: Respiratory Care - August 21, 2023 Category: Respiratory Medicine Authors: Valentina Marziano Giorgio Guzzetta Francesco Menegale Chiara Sacco Daniele Petrone Alberto Mateo Urdiales Martina Del Manso Antonino Bella Massimo Fabiani Maria Fenicia Vescio Flavia Riccardo Piero Poletti Mattia Manica Agnese Zardini Valeria d'Andrea Fi Source Type: research
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
We describe simultaneous influenza and mRNA COVID-19 bivalent booster vaccine administration between August 31-December 31, 2022, among persons aged ≥6 months in the Vaccine Safety Datalink (VSD) by COVID-19 bivalent booster vaccine type, influenza vaccine type, age group, sex, and race and ethnicity. Of 2,301,876 persons who received a COVID-19 bivalent booster vaccine, 737,992 (32.1%) received simultaneous influenza vaccine, majority were female (53.1%), aged ≥18 years (91.4%), and non-Hispanic White (55.7%). These findings can inform future VSD studies on simultaneous influenza and COVID-19 bivalent booster vaccine ...
Source: Vaccine - August 20, 2023 Category: Allergy & Immunology Authors: Tat'Yana A Kenigsberg Kristin Goddard Kayla E Hanson Ned Lewis Nicola Klein Stephanie A Irving Allison L Naleway Bradley Crane Tia L Kauffman Stanley Xu Matthew F Daley Laura P Hurley Robyn Kaiser Lisa A Jackson Amelia Jazwa Eric S Weintraub Source Type: research
